Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors possessing augmented P2' side chains
Smith III, A.B., Charnley, A.K., Harada, H., Beiger, J.J., Cantin, L.D., Kenesky, C.S., Hirschmann, R., Munshi, S., Olsen, D.B., Stahlhut, M.W., Schleif, W.A., Kuo, L.C.(2006) Bioorg Med Chem Lett 16: 859-863
- PubMed: 16298527 
- DOI: https://doi.org/10.1016/j.bmcl.2005.11.011
- Primary Citation of Related Structures:  
2BB9, 2BBB - PubMed Abstract: 
A series of monopyrrolinone-based HIV-1 protease inhibitors possessing rationally designed P2' side chains have been synthesized and evaluated for activity against wild-type HIV-1 protease. The most potent inhibitor displays subnanomolar potency in vitro for the wild-type HIV-1 protease. Additionally, the monopyrrolinone inhibitors retain potency in cellular assays against clinically significant mutant forms of the virus. X-ray structures of these inhibitors bound in the wild-type enzyme reveal important insights into the observed biological activity.
Organizational Affiliation: 
Department of Chemistry, University of Pennsylvania, Philadelphia, PA 19104, USA. smithhab@sas.upenn.edu